false 0001716621 0001716621 2025-10-10 2025-10-10
  
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
 
October 10, 2025
 
 
Catheter Precision, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
  
001-38677
  
38-3661826
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
 
1670 Highway 160 West
Suite 205
Fort Mill, SC 29708
(Address of principal executive offices, including zip code)
 
(973) 691-2000
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
VTAK
NYSE American
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.07 Submission of Matters to a Vote of Security Holders. 
 
On October 10, 2025, the Company held a Special Meeting of stockholders at which, of the 1,487,266 shares of the Company’s common stock outstanding as of September 10, 2025, the record date for the Annual Meeting, 641,616 shares of common stock were represented, either in person or by proxy, constituting, of the shares entitled to vote, approximately 43.1% of the outstanding shares of common stock. 
 
At the Annual Meeting, the Company’s stockholders considered three proposals, which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on September 15, 2025. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below: 
 
 
1.
Proposal No. 1: To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from sixty (60) million shares to five hundred (500) million shares. Proposal No. 1 was approved, based on the following results of voting:
 
Votes For
  
Votes Against
Abstentions
Broker Non-Votes
497,162
  
133,882
10,571
0
 
 
2.
Proposal No. 2: To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. Proposal No. 2 was approved, based on the following results of voting:
 
 
Votes For
  
Votes Against
Abstentions
Broker Non-Votes
610,134
  
16,778
14,703
0
 
 
3.
Proposal No. 3: To approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos 1 and/or 2. Proposal No. 3 was approved, based on the following results of voting:
 
Votes For
  
Votes Against
Abstentions
Broker Non-Votes
514,362
  
120,394
6,860
0
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
CATHETER PRECISION, INC.
         
       
         
Date:
  
October 15, 2025
By:
/s/ Philip Anderson
       
Philip Anderson
       
Chief Financial Officer